Method of treating otic infections with moxifloxacin compositions
View Patent ↗Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
1. A method of treating otic infections commonly associated with at least one of P. aeruginosa and H. influenzae , which comprises topically applying to the affected otic tissue a therapeutically effective amount of a topical otic pharmaceutical composition comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of 0.1 to 1.0 wt. % and a pharmaceutically acceptable vehicle therefor.
2. A method of treating otic infections commonly associated with at least one of P. aeruginosa and H. influenzae and attendant inflammation, which comprises topically applying to the affected otic tissue a therapeutically effective amount of a topical otic pharmaceutical composition comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of 0.1 to 1.0 wt. %, an anti-inflammatory effective amount of a steroidal or non-steroidal anti-inflammatory agent, and a pharmaceutically acceptable vehicle therefor.
3. A method according to claim 2 , wherein the anti-inflammatory agent comprises a glucocorticoid.
4. A method according to claim 3 , wherein the glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide.
5. A method according to claim 2 , wherein the anti-inflammatory agent comprises a non-steroidal agent selected from the group consisting of prostaglandin H synthetase inhibitors, PAF antagonists, and PDE IV inhibitors.
6. A method according to claim 2 , wherein the anti-inflammatory agent comprises dexamethasone.
7. A method according to claim 2 , wherein the anti-inflammatory agent comprises nepafenac.
8. A topical composition method according to any one of claims 1 , 2 , 6 or 7 , wherein the composition contains moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of about 0.35 wt. %.
9. A method according to any one of claims 1 , 2 , 6 , and 7 , wherein the composition contains moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of 0.35 to 1 wt. %.